Apart from the above, Aadhar Housing Finance, ABC Gas, Blue Star, Endurance Technologies, Gujarat Gas, Hi-Tech Pipes, JK Lakshmi Cement, KP Energy, RITES, Shipping Corp, Spencers Retail, Virinchi, Trident, Wardwizard Innovations and a few others will announce their quarterly results.
Tata Steel Q2 expectations
Tata Steel is expected to face continued challenges due to declining realizations and rising costs in both its domestic and European operations, according to brokerage estimates.
EBITDA for the September quarter may decline anywhere between 12-17% quarter-on-quarter, according to estimates from five brokerages.
Phillip Capital anticipates a consolidated net loss of Rs 133.6 crore year-on-year (YoY), with revenues expected to rise marginally by 0.3% YoY to Rs 55,863.6 crore. Whereas, Elara Capital estimates a higher net loss of Rs 153.1 crore.Nuvama projects Tata Steel’s standalone EBITDA per tonne to decline by Rs 1,960 QoQ, reaching Rs 11,710 per tonne. This drop is attributed to a reduction in realizations by Rs 2,400 per tonne, partly mitigated by a decrease in coking coal prices.In Europe, losses are expected to deepen, with an anticipated EBITDA loss of -$77 per tonne, up from -$28 in Q1FY25, primarily due to lower steel prices in the Netherlands and losses from UK operations, where blast furnaces are being shut down.
Apollo Hospitals Q2 expectations
The company is expected to report strong numbers in the second quarter, led by growth across all segments. Revenues are likely to rise up to 14% year-on-year, and profit for the quarter is seen jumping 54% year-on-year, according to Kotak Equities.
“We bake in 13% YoY sales growth in the hospitals segment in 2QFY25, led by volume pick-up and better occupancies. We expect ARPOB growth to remain moderated due to higher secondary procedures,” the brokerage said.
HealthCo sales are likely to grow 15% YoY, driven by growth in pharmacy distribution sales on account of the store expansion as well as traction in 24/7.
EBITDA for the September quarter is seen rising 14% YoY to Rs 720 crore due to higher volumes, growth in specialty segment in Apollo Health, and reduced opex in Apollo 24/7.
“With enhanced footfalls in primary care, lower customer acquisition costs, and focus on omni-channel, Apollo Health is expected to register 7.8% YoY revenue growth and 40% YoY EBITDA growth,” Motilal Oswal said.
(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of Economic Times)